Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

atrial fibrillation - prevention - patients without history of AF (primary prevention)  


Related trials

GISSI HF (subgroup and ancillary study), 2009 - rosuvastatin vs placebo

ARMYDA-3, 2006 - atorvastatin vs placebo

Chello, 2006 - atorvastatin vs placebo

LIFE, 2005 - losartan vs atenolol

CHARM, 2005 - candesartan vs placebo

Val-HeFT, 2003 - valsartan vs placebo

GISSI-3, 2003 - lisinopril vs placebo

SOLVD, 2003 - enalapril vs placebo

MIRACL, 2001 - atorvastatin vs placebo

TRACE, 1999 - trandolapil vs placebo

VA HIT, 1999 - gemfibrozil vs placebo



See also:

  • All atrial fibrillation clinical trials
  • All clinical trials of prevention
  • All clinical trials of atorvastatin
    		•  

    ARMYDA-3 study, 2006

    Treatments

    Studied treatment atorvastatin 40mg daily
    Control treatment placebo

    Patients

    Patients patients with scheduled cardiac surgery without history of AF
    Baseline characteristics
    Age (yr) 66 y 
    Hypertension (%) 87% 
    Diabetes (%) 37% 
    CAD (%) 84% 
    LVEF (%) 52% 
    beta-blocker use (%) 66% 
    ACEI (%) 49% 

    Method and design

    Randomized effectives 101 / 99 (studied vs. control)
    Follow-up duration 30 days
    Primary endpoint post-operative AF 5 min


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    atrial fibrillation

    35 / 101
         56 / 99
         0,61 [0,45;0,84]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    atrial fibrillation 35 / 101 (34,7%) 56 / 99 (56,6%) 0,61 [0,45;0,84]   11054 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11054: Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty DAntiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.J Am Coll Cardiol 2008;51:828-35

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    atrial fibrillation 34,65% 56,57% -219,1‰


    Reference(s)

    Trials register # NA
    • Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.. Circulation 2006;114:1455-61
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend